ImaRx Therapeutics Transitions Busines...(s research and development efforts are f...),Health

About Urokinase

In 2006, ImaRx acquired urokinase and all related assets, including approximately a four-year supply of inventory as well as cell lines and manufacturing rights to the drug. Since October 2006, ImaRx has been selling its urokinase inventory in the U.S. market, where it is estimated to be listed on pharmacy formularies at approximately 700 acute care hospitals.

Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism, or blood clots in the lungs. The product has been commercialized for more than 20 years and has been administered to greater than four million patients.

On January 22, 2008 the Company announced that it had entered into a letter of intent with Microbix Biosystems for the manufacture of a long term supply of urokinase. This agreement would allow ImaRx to explore the development of additional indications for the drug, continue to serve its current customers beyond its existing inventory and expand product sales to additional vascular physicians and acute care institutions.

About SonoLysis

ImaRx's SonoLysis program involves the administration of its proprietary MRX-801 microbubbles and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The sub-micron size of MRX-801 microbubbles may allow them to penetrate a blood clot, so that when ultrasound is applied their expansion and contraction, or cavitation, can break the clot into very small particles. This technology was most recently evaluated in a Phase I/II clinical trial in combination with tPA in patients suffering from acute ischemic stroke.

According to Andrei Alexandrov, MD, Director of the Comprehensive Stroke Research Center at the University of Alabama, Birmingham. "Stroke remains a challenging thera
'/>"/>